T1	intervention 52 61	idoxifene
T2	total-participants 390 392	56
T3	eligibility 393 475	postmenopausal patients with progressive locally advanced/metastatic breast cancer
T4	control 579 588	tamoxifen
T5	total-participants 692 694	47
T6	intervention-participants 727 729	25
T7	control-participants 741 743	22
T8	outcome 760 777	partial responses
T10	outcome 854 883	overall clinical benefit rate
T11	iv-bin-abs 756 759	two
T12	iv-bin-abs 782 785	two
T13	iv-bin-percent 884 887	16%
T15	iv-cont-median 952 962	9.8 months
T16	outcome 980 999	objective responses
T17	cv-bin-abs 977 979	no
T18	cv-bin-abs 1067 1070	two
T9	outcome 786 813	disease stabilizations (SD)
T19	outcome 1084 1086	SD
T20	outcome 1108 1129	clinical benefit rate
T21	cv-bin-percent 1130 1132	9%
T22	outcome 1208 1231	drug-related toxicities
T23	outcome 1283 1294	hot flushes
T24	iv-bin-percent 1295 1298	13%
T25	cv-bin-percent 1302 1305	15%
T26	outcome 1307 1318	mild nausea
T27	iv-bin-percent 1319 1322	20%
T28	cv-bin-percent 1326 1329	15%
T14	outcome 912 947	median duration of clinical benefit
T29	outcome 1580 1604	serum cholesterol levels
T30	outcome 1413 1471	serum follicle-stimulating hormone and luteinizing hormone
